

PUBBLICAZIONI DR. CASSINOTTI 2005-2020

- 1) **Cassinotti A**, Fociani P, Duca P, Nebuloni M, Campbell Davies SE, Sampietro G, Buffoli F, Corona A, Maconi G, Ardizzone S. Modified Kudo classification can improve the accuracy of virtual chromoendoscopy with FICE in the endoscopic surveillance of ulcerative colitis. *Endoscopy Intern Open* 2020; *in press*.
- 2) **Cassinotti A**, Buffoli F, Fociani P, Staiano T, Villanacci V, Nebuloni M, Duca P, Fichera M, Grassia R, Manes G, Salemme M, Molteni P, Sampietro G, Foschi D, de Franchis R, Ardizzone S. Virtual chromoendoscopy with FICE for the classification of polypoid and nonpolypoid raised lesions in ulcerative colitis. *J Clin Gastroenterol*. 2019;53:269-276.
- 3) Fiorino G, Sturniolo GC, Bossa F, **Cassinotti A**, di Sabatino A, Giuffrida P, Danese S. A Phase 2°, multi center, randomized, double-blind, parallel-group, placebo controlled trial of IBD98-M delayed-release capsule to induce remission in patients with active and mild to moderate ulcerative colitis. *Cells* 2019;8(6) doi: 10.3390/cells8060523
- 4) Brierley CK, Castilla-Llorente C, Labopin M, Badoglio M, Rovira M, Ricart E, Dierickx D, Vermeire S, Hasselblatt P, Finke J, Onida F, **Cassinotti A**, Satsangi J, Kazmi M, Lopez-Sanroman A, Schmidt C, Farge D, Travis SPL, Hawkey CJ, Snowden JA. Autologous hematopoietic stem cell transplantation for Crohn's disease: a retrospective survey of long-term outcomes from the European Society for Blood and Marrow Transplantation. *J Crohn's Colitis* 2018;12:1097-1103.
- 5) Zanutto S, Ciniselli CM, Belfiore A, Lecchi M, Masci E, Delconte G, Primignani M, Tosetti G, Dal Fante M, Fazzini L, Airoidi A, Vangeli M, Turpini F, Rubis Passoni GG, Viaggi P, Arena M, Motta RIO, Cantù AM, Crosta C, De Roberto G, Iannuzzi F, **Cassinotti A**, Dall'Olio V, Tizzoni L, Sozzi G, Meroni E, Bisanti L, Pierotti MA, Verderio P, Gariboldi M. Plasma miRNA-based signatures in CRC screening programs. *Int J Cancer* 2020;146:1164-1173.
- 6) Maconi G, Mezzina N, Landi S, Grillo S, Bezzio C, Bosani M, Pastorelli L, Dell'Era A, Chibbar R, Carmagnola S, Molteni P, **Cassinotti A**, Massari A, Ardizzone S. Use, effectiveness and tolerability of budesonide-MMX in ulcerative colitis: A real-life experience. *United European Gastroenterology Journal* 2019;7:1164-1170
- 7) Sampietro GM, Colombo F, Frintali A, Baldi CM, Carmagnola S, **Cassinotti A**, Dell'Era A, Massari A, Molteni P, Dilillo D, Fociani P, Tonolini M, Maconi G, Fiorina P, Corsi F, Bianco R, Nebuloni M, Zuccotti G, Ardizzone S, Foschi D. Totally laparoscopic, multi-stage, restorative proctocolectomy for inflammatory bowel diseases. A prospective study on safety, efficacy and long-term results. *Dig Liver Dis* 2018;50:1283-1291.
- 8) Daperno M, Comberlato M, Bossa F, Armuzzi A, Blancon L, Bonanomi AG, **Cassinotti A**, Cosentino R, Lombardi G, Mangiarotti R, Papa A, Pica R, Grassano L, Pagana G, D'Inca R, Orlando A, Rizzello F; IGIBDendo Group. Training programs on endoscopic scoring systems for inflammatory bowel disease lead to a significant increase in interobserver agreement among community gastroenterologists. *J Crohn's Colitis* 2017;11:556-561.
- 9) Daperno M, Comberlato M, Bossa F, Biancone L, Bonanomi AG, **Cassinotti A**, Cosentino R, Lombardi G, Mangiarotti R, Papa A, Pica R, Rizzello F, D'Inca R, Orlando A. Inter-observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG-IBD). *Dig Liver Dis* 2014;46:969-73.
- 10) Forni D, Cleynen I, Ferrante M, **Cassinotti A**, Cagliani R, Ardizzone S, Vermeire S, Fichera M, Lombardini M, Maconi G, de Franchis R, Asselta R, Biasin M, Clerici M, Sironi M. ABO histo-blood group might modulate predisposition to Crohn's disease and affect disease behaviour. *J Crohns Colitis* 2014;8:489-94.

- 11) Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D'Inca R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzzello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G. Attendees: Aratari A, Bortoli A, Bossa F, Cappello M, **Cassinotti A**, Chiriatti A, Fiorino G, Formica V, Guidi L, Losco A, Mocciaro F, Onali S, Pastorelli L, Pica R, Principi M, Renna S, Ricci C, Rispo A, Rogai F, Sarmati L, Scaldaferrì F, Spina L, Tambasco R, Testa A, Viscido A. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). *Dig Liver Dis* 2017;49:338–358
- 12) **Cassinotti A**, Sarzi-Puttini P, Fichera M, Shoenfeld Y, de Franchis R, Ardizzone S. Immunity, autoimmunity and inflammatory bowel disease. *Autoimmun Rev* 2014;13:1-2.
- 13) Manes G, Ardizzone S, **Cassinotti A**. PillCam colon and ulcerative colitis: what do physicians need to know? *Endoscopy* 2013;45:325.
- 14) Cagliani R, Pozzoli U, Forni D, **Cassinotti A**, Fumagalli M, Giani M, Fichera M, Lombardini M, Ardizzone S, Asselta R, de Franchis R, Riva S, Biasin M, Comi GP, Bresolin N, Clerici M, Sironi M. Crohn's disease loci are common targets of protozoa-driven selection. *Mol Biol Evol* 2013;30:1077-87.
- 15) Atzeni F, Talotta R, Benucci M, Salaffi F, **Cassinotti A**, Varisco V, Battellino M, Ardizzone S, Pace F, Sarzi-Puttini P. Immunogenicity and autoimmunity during anti-TNF therapy. *Autoimmun Rev* 2013;12:703-8
- 16) Ardizzone S, **Cassinotti A**, de Franchis R. Immunosuppressive and biologic therapy for ulcerative colitis. *Expert Opin Emerg Drugs* 2012;17:449-67.
- 17) Guerini FR, Cagliani R, Forni D, Agliardi C, Caputo D, **Cassinotti A**, Galimberti D, Fenoglio C, Biasin M, Asselta R, Scarpini E, Comi GP, Bresolin N, Clerici M, Sironi M. A functional variant in ERAP1 predisposes to multiple sclerosis. *PLoS One* 2012;7:e29931.
- 18) Clerici M, **Cassinotti A**, Onida F, Trabattoni D, Annaloro C, Volpe AD, Rainone V, Lissoni F, Duca P, Sampietro G, Fociani P, Vago G, Foschi D, Ardizzone S, Deliliers GL, Porro GB. Immunomodulatory effects of unselected haematopoietic stem cells autotransplantation in refractory Crohn's disease. *Dig Liver Dis* 2011;43:946-52.
- 19) Sironi M, Guerini FR, Agliardi C, Biasin M, Cagliani R, Fumagalli M, Caputo D, **Cassinotti A**, Ardizzone S, Zanzottera M, Bolognesi E, Riva S, Kanari Y, Miyazawa M, Clerici M. An evolutionary analysis of RAC2 identifies haplotypes associated with human autoimmunity diseases. *Mol Biol Evol* 2011;28:3319-29
- 20) Ardizzone S, **Cassinotti A**, Bevilacqua M, Clerici M, Porro GB. Vitamin D and inflammatory bowel disease. *Vitam Horm* 2011;86:367-77.
- 21) Ardizzone S, **Cassinotti A**, Duca P, Mazzali C, Penati C, Manes G, Marmo R, Massari A, Molteni P, Maconi G, Porro GB. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. *Clin Gastroenterol Hepatol* 2011;9:483-89.
- 22) **Cassinotti A**, Fichera M, Ardizzone S, Bianchi Porro G. Is mucosal healing a predictor of decreased risk of Crohn's disease relapse after withdrawal of 1-year, successful adalimumab? *Dig Liver Dis Supplements* 2010;4:18-21
- 23) Ardizzone S, **Cassinotti A**, Manes G, Bianchi Porro G. Immunomodulators for all patients with inflammatory bowel disease? *Ther Adv Gastroenterol* 2010;3:31-42.

- 24) Annunziata ML, Bossa F, Bozzi R, Caprioli F, **Cassinotti A**, Costantino G, Fiorino G, Onali S, Principi M, Renna S, Tambasco R. The Italian clinical experience with adalimumab in Crohn's disease: eleven clinical cases. *Dig Liver Dis Supplements* 2010;4:1-3.
- 25) Bergamaschi G, Di Sabatino A, Alberini R, Ardizzone S, Biancheri P, Sonetti E, **Cassinotti A**, Cazzola P, Markopoulos K, Massari A, Rosti V, Bianchi Porro G, Corazza GR. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-Tumor Necrosis Factor-alpha treatment. *Haematol-Hematol J* 2010;95:199-205.
- 26) **Cassinotti A**, Actis GC, Duca P, Massari A, Colombo E, Gai E, Annese V, D'Albasio G, Manes G, Travis S, Bianchi Porro G, Ardizzone S. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal. *Am J Gastroenterol* 2009;104:2760-7.
- 27) **Cassinotti A**, Keshav S, Ardizzone S, Mortensen N, Sampietro G, Fociani P, Duca P, Gorge B, Lazzaroni M, Manes G, Warren B, Foschi D, Vago G, Bianchi Porro G, Travis S. IBD care in Europe: A comparative audit of the inpatient management of Crohn's disease and ulcerative colitis using the National UK IBD Audit Tool. *J Crohn's Colitis* 2009;3:291-301.
- 28) **Cassinotti A**, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. *Inflamm Bowel Dis* 2009;15:1264-75.
- 29) **Cassinotti A**, Birindelli S, Clerici M, Trabattoni D, Lazzaroni M, Ardizzone S, Colombo R, Rossi E, Bianchi Porro G. HLA and autoimmune digestive disease: a clinically-oriented review for gastroenterologists. *Am J Gastroenterol* 2009;104:195-217.
- 30) Ardizzone S, **Cassinotti A**, Trabattoni D, Manzionna G, Rainone V, Bevilacqua M, Massari A, Maconi G, Clerici M, Bianchi Porro G. Immunomodulatory effects of 1,25-dihydroxyvitamin D₃ on Th1/Th2 cytokines in inflammatory bowel disease: an *in vitro* study. *Int J Immunopathol Pharmacol* 2009;22:63-71.
- 31) Manes G, Imbesi V, Ardizzone S, **Cassinotti A**, Pallotta S, Bianchi Porro G. Use of double-balloon enteroscopy in the management of patients with Crohn's disease: feasibility and diagnostic yield in a high-volume centre for inflammatory bowel disease. *Surg Endosc* 2009;23:2790-95.
- 32) Maconi G, Colombo E, Sampietro GM, Lamboglia F, D'Incà R, Daperno M, **Cassinotti A**, Sturniolo GC, Ardizzone S, Duca D, Bianchi Porro G, Annese V. CARD15 gene variants and risk of re-operation in Crohn's disease patients. *Am J Gastroenterol* 2009;104:195-217.
- 33) Angelucci E, Orlando A, Ardizzone S, Guidi L, Sorrentino D, Fries W, Astegiano M, Sociale O, Cesarini M, Renna S, **Cassinotti A**, Marzo M, Quaglia A, Sergi MD, Vernia P, Danese S. Internet use among Inflammatory Bowel Disease patients: An Italian multicenter survey. *Eur J Gastroenterol Hepatol* 2009;21:1036-41.
- 34) Manes G, Imbesi V, Ardizzone S, **Cassinotti A**, Bosani M, Massari A, Bianchi Porro G. Use of colonoscopy in the management of patients with Crohn's disease: appropriateness and diagnostic yield. *Dig Liver Dis* 2009;41:653-58.
- 35) **Cassinotti A**, Annaloro C, Ardizzone S, Onida F, Della Volpe A, Clerici M, Usardi P, Greco S, Maconi G, Bianchi Porro G, Lambertenghi Delilieri G. Autologous haematopoietic stem cell transplantation without CD34⁺ cell selection in refractory Crohn's disease. *Gut* 2008;57:211-7.
- 36) Ardizzone S, Puttini PS, **Cassinotti A**, Bianchi Porro G. Extraintestinal manifestations of inflammatory bowel disease. *Dig Liver Dis* 2008;40S2:S253-S259.
- 37) Manes G, Imbesi V, Ardizzone S, **Cassinotti A**, Bosani M, Massari A, Bianchi Porro G. Appropriateness and diagnostic yield of colonoscopy in the management of patients with ulcerative colitis: A prospective study in an open access endoscopy service. *Inflamm Bowel Dis* 2008;14:1133-8.

- 38) Maconi G, Greco S, Duca P, Ardizzone S, Massari A, **Cassinotti A**, Radice E, Bianchi Porro G. Prevalence and clinical significance of sonographic evidence of mesenteric fat alterations in Crohn's disease. *Inflamm Bowel Dis* 2008;14:1555-61
- 39) Greco S, **Cassinotti A**, Massari A, Bossi I, Trabucchi E, Bianchi Porro G. Isolated ampullary adenoma causing biliary obstruction. *J Gastrointest Liver Dis.* 2008;17:329-32.
- 40) **Cassinotti A**, Massari A, Ferrara E, Greco S, Bosani M, Ardizzone S, Bianchi Porro G. New onset of atrial fibrillation after introduction of azathioprine in ulcerative colitis: case report and review of the literature. *Eur J Clin Pharmacol* 2007;63:875-8.
- 41) Bianchi Porro G, **Cassinotti A**, Ferrara E, Maconi G, Ardizzone S. Review article: management of steroid dependency in ulcerative colitis. *Aliment Pharmacol Ther* 2007;26:779-94.
- 42) Ardizzone S, Maconi G, **Cassinotti A**, Massari A, Bianchi Porro G. Imaging of perianal Crohn's disease. *Dig Liver Dis* 2007;39:970-8.
- 43) Ardizzone S, Maconi G, Bianchi V, Russo A, Colombo E, **Cassinotti A**, Penati C, Tenchini ML, Bianchi Porro G. Multidrug resistance 1 gene polymorphism and susceptibility to inflammatory bowel disease. *Inflamm Bowel Dis* 2007;13:516-523.
- 44) Maconi G, Colombo E, Zerbi P, Sampietro GM, Fociani P, Bosani M, **Cassinotti A**, Casini V, Russo A, Ardizzone S, Porta M, Bianchi Porro G. Prevalence, detection rate and outcome of cytomegalovirus infection in ulcerative colitis patients requiring colonic resection. *Dig Liver Dis* 2005;37:418-23.
- 45) Orlando A, Colombo E, Kohn A, Biancone L, Rizzello F, Viscido A, Sostegni R, Benazzato L, Castiglione F, Papi C, Meucci C, Riegler G, Mocciaro F, **Cassinotti A**, Cosentino R, Geremia A, Morselli C, Angelucci E, Lavagna A, Rispo A, Bossa F, Scimeca D, Cottone M. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study. *Dig Liver Dis* 2005; 37:577-83.
- 46) Maconi G, Di Sabatino A, Ardizzone S, Greco S, Colombo E, Russo A, **Cassinotti A**, Casini V, Corazza GR, Bianchi Porro G. Prevalence and clinical significance of sonographic detection of enlarged regional lymph nodes in Crohn's disease. *Scand J Gastroenterol* 2005;40:1328-33.
- 47) Piras C, Soggiu A, Greco V, **Cassinotti A**, Maconi G, Ardizzone S, Amoresano A, Porro GB, Bonizzi L, Roncada P. Serum protein profiling of early and advanced stage Crohn's disease. *EuPA Open Proteomic* 2014;3:48-59
- 48) **Cassinotti A**. Crohn's disease. In *Imaging of perianal inflammatory diseases*. 2014, pgg 31-38. Tonolini and Maconi eds. Publisher Springer Milan.
- 49) **Cassinotti A**, Travis S. Why Don't We Just Measure Infliximab Drug Levels in IBD? *Practical Gastroenterology* 2010;34:11-20.
- 50) **Cassinotti A**, Muzio F, Ardizzone S, Bianchi Porro G. Algoritmi diagnostico-terapeutici di nutrizione artificiale nelle malattie infiammatorie croniche intestinali. In *Aggiornamenti in nutrizione clinica e patologie correlate*. 2010. Mattioli ed.
- 51) Ardizzone S, **Cassinotti A**. Cancro coloretale nelle IBD: aspetti clinico-terapeutici. In *Displasia e cancro coloretale nelle malattie infiammatorie croniche intestinali*. Elsevier ed. 2010.
- 52) **Cassinotti A**, Bianchi Porro G. The ABCs of chronic inflammatory bowel disease – Part I: From pathogenesis to clinical approach [L'ABC delle malattie infiammatorie croniche intestinali]. *Argomenti di Gastroenterologia Clinica* 2009;22:I-XXIII

- 53) Ardizzone S, **Cassinotti A**, Bianchi Porro G. The autologous transplant of hematopoietic stem cells in the treatment of Crohn's disease: Preliminary results and future prospective (Editorial). [Il trapianto autologo di cellule staminali ematopoietiche nel trattamento della malattia di Crohn: Risultati preliminari e prospettive future]. *Argomenti di Gastroenterologia Clinica* 2007;20:3-4.
- 54) **Cassinotti A**, Ardizzone S, Bianchi Porro G. La colite ulcerosa steroide-dipendente: quale terapia? In *IBD Year Book 2008*. Bianchi Porro, Ardizzone, Radice eds. Nomos Edizioni, 2008.
- 55) Radice E, Ardizzone S, **Cassinotti A**. Is mucosal healing an important endpoint in IBD? In *IBD Year Book 2008*. Bianchi Porro, Ardizzone, Radice eds. Nomos Edizioni, 2008.
- 56) **Cassinotti A**, Bianchi Porro G. ABC delle malattie infiammatorie croniche intestinali. Parte I: dalla patogenesi all'approccio clinico. *Argomenti di Gastroenterologia Clinica* Vol. 22 n. 1, Marzo 2009. Masson ed.
- 57) **Cassinotti A**, Ardizzone S, Bianchi Porro G. Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn's disease. *Core Evidence* 2007;2:209-224.
- 58) **Cassinotti A**, Ardizzone S, Bianchi Porro G. Adalimumab for the treatment of Crohn's disease. *Biologics* 2008;2:753-77.
- 59) Ardizzone S, Radice E, **Cassinotti A**, Ferrara E, Maconi G, Bianchi Porro G. Sono gli immunosoppressori convenzionali i farmaci di prima scelta nel trattamento delle malattie infiammatorie croniche intestinali? In *IBD Year Book 2007*. Bianchi Porro, Ardizzone, Radice eds. Nomos Edizioni, 2007.
- 60) **Cassinotti A**, Bianchi Porro G. Prospettive in tema di terapia delle malattie infiammatorie croniche intestinali. In *IBD Year Book 2007*. Bianchi Porro, Ardizzone, Radice eds. Nomos Edizioni, 2007.
- 61) **Cassinotti A**, Onida F, Lambertenghi Deliliers G, Bianchi Porro G. Nuove opzioni di terapia nel morbo di Crohn refrattario. Il trapianto autologo di cellule staminali emopoietiche. *Medico e Paziente* 2008;4:14-18.
- 62) **Cassinotti A**, Bianchi Porro G. Editoriale: la leucocitoafesi nella colite ulcerosa. *Argomenti di Gastroenterologia Clinica* 2006;19:5-6.
- 63) Ardizzone S, Penati C, Radice E, Ferrara E, Bosani M, **Cassinotti A**, Imbesi V, Colombo E, Maconi G, Bianchi Porro G. Terapia medica della colite ulcerosa refrattaria. In: *La gastropatia da FANS: dopo il caso Vioxx. La colite ulcerosa: progressi terapeutici*; [a cura di] G. Bianchi Porro, M. Bosani, L. Pastore - Verona: Edizioni Libreria Cortina, 2006.
- 64) **Cassinotti A**. Diagnostic role of PCR in gastroenterology. [La PCR in gastroenterologia]. *Argomenti di Gastroenterologia Clinica* 2006;19:4-10.
- 65) **Cassinotti A**, Bianchi Porro G. Editoriale: Mycobacterium paratuberculosis e morbo di Crohn: nuovi riscontri per un ruolo ritrovato. *Argomenti di Gastroenterologia clinica* 2005;18:3-4.
- 66) **Cassinotti A**. Il punto su...L'alitosi. *Argomenti di Gastroenterologia clinica* 2005;18:40-44.